ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-07

Price

$114.80

+0.07%

Score6.1Priority

Signals7/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.7xvs 20d avg

Analysis

Gilead Sciences is acquiring Arcellx for $115 per share in cash plus a $5 Contingent Value Right (CVR), anchoring the stock's price action just cents below the offer. Despite Gilead extending the tender offer deadline to April 24 due to low initial participation, the stock remains pinned at $114.80, demonstrating textbook Institutional Absorption by merger arbitrage funds. Technical signals like QUIET_STORM and ALPHA_MALE confirm this tight, highly supported accumulation. Furthermore, the RISK_ON macro regime and exceptionally low credit spreads (OAS 0.85%) provide high conviction that corporate financing is secure and the deal will close without macro liquidity friction.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable thesis: Capitalize on the merger arbitrage spread up to the $115 cash offer, viewing the additional $5 CVR (payable in 2030 based on anito-cel sales) as free upside optionality.
Key risk: Failure to reach the 50% tender threshold by the new April 24 deadline could force further extensions, introducing time-value decay and minor downside risk.
What to watch: Monitor tender participation rates and institutional accumulation heading into the late April deadline, as HSR antitrust clearance has already been secured.

← Back to 2026-04-07 View Full ACLX History →Yahoo Finance &nearr;